Vontobel Holding Ltd. Has $283,000 Stake in Certara, Inc. $CERT

Key Points

• Vontobel Holding Ltd. has significantly reduced its stake in Certara, Inc. by 76.9%, now holding 24,193 shares worth $283,000.
• Analysts have mixed ratings on Certara, with Barclays raising their price target to $16.00 and Zacks upgrading their rating from "strong sell" to "hold," while UBS lowered their target from $17.50 to $15.00.
• Insider Leif E. Pedersen sold 51,224 shares of Certara, representing a 40.91% decrease in their position, bringing their remaining shares to a valuation of approximately $807,850.

Vontobel Holding Ltd. trimmed its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 76.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,193 shares of the company's stock after selling 80,549 shares during the period. Vontobel Holding Ltd.'s holdings in Certara were worth $283,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. AdvisorNet Financial Inc bought a new stake in shares of Certara during the 2nd quarter worth about $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Certara during the first quarter worth approximately $31,000. AlphaQuest LLC acquired a new stake in Certara during the first quarter worth approximately $39,000. Quarry LP bought a new position in shares of Certara during the first quarter worth approximately $98,000. Finally, Associated Banc Corp bought a new position in shares of Certara during the first quarter worth approximately $101,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CERT has been the topic of a number of research reports. Barclays upped their price objective on Certara from $14.00 to $16.00 and gave the company an "overweight" rating in a report on Thursday, October 2nd. Craig Hallum initiated coverage on shares of Certara in a research report on Monday, September 29th. They issued a "buy" rating and a $16.00 target price for the company. Zacks Research upgraded shares of Certara from a "strong sell" rating to a "hold" rating in a research note on Friday, September 5th. Weiss Ratings reiterated a "sell (d)" rating on shares of Certara in a research note on Wednesday, October 8th. Finally, UBS Group lowered their target price on shares of Certara from $17.50 to $15.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $15.63.

Insiders Place Their Bets

In related news, insider Leif E. Pedersen sold 51,224 shares of the business's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total transaction of $559,366.08. Following the sale, the insider owned 73,979 shares in the company, valued at $807,850.68. The trade was a 40.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.33% of the stock is owned by corporate insiders.

Certara Trading Up 0.6%

CERT opened at $11.97 on Thursday. The company's 50 day moving average is $11.47 and its 200-day moving average is $11.46. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $15.69. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.92 billion, a P/E ratio of 239.45 and a beta of 1.45.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. Certara had a net margin of 1.97% and a return on equity of 5.11%. Certara's revenue for the quarter was up 12.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.07 EPS. Equities research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.